Media

March 28, 2024

Organon Canada Receives Health Canada Medical Device Licence (MDL) Approval for the JADA^TM System Intended to Control and Treat Abnormal Postpartum Uterine Bleeding or Hemorrhage

March 8, 2024

On International Women’s Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women’s health

January 22, 2024

Organon Canada confirms no quality issue for PROMETRIUM®

October 26, 2023

Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to Humira

September 26, 2023

On World Contraception Day, Organon Canada declares support for universal access to contraception in Canada

May 18, 2023

Organon Canada to support Le Chaînon by funding the initial construction phase of its medical clinic

March 3, 2023

Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplace

February 27, 2023

Ahead of International Women’s Day, Organon Canada Spotlights the Importance of Supporting Women’s Equity While Highlighting the Cost of Not Investing in Their Health

January 5, 2023

Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy

December 20, 2022

Organon Canada welcomes the Ontario Drug Benefit Biosimilars Initiative

September 26, 2022

On World Contraception Day, Organon wants to help tackle the global issue of unintended pregnancies by helping ensure women make informed decisions about their reproductive health

July 28, 2022

Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate

June 17, 2022

This World Infertility Awareness Month, Organon Canada is committed to listening and highlighting different paths and barriers to parenthood

June 13, 2022

Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates

June 2, 2022

Organon Introduces Global Environmental, Social and Governance (ESG) Strategy and Commitments with Publication of Inaugural ESG Report

February 2, 2022

Organon Canada declares paid time off for all employees on International Women’s Day.

September 22, 2021

Organon wants to help women take control of their birth control

June 21, 2021

Organon Canada Launches as New Women’s Health Company

For media inquiries about Organon Canada please contact our Media Centre:

1-450-366-1740
media_canada@organon.com